Latest News for: nktr

Edit

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

PR Newswire 21 Mar 2026
NEW YORK, March 21, 2026 /PRNewswire/ --. Why ... NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. So what ... What to do next ... Why Rosen Law ... A. 21% ... .
Edit

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

PR Newswire 20 Mar 2026
NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission ... If you are a shareholder who suffered a loss, click here to participate ... CONTACT. ... 21%.
Edit

NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar

The Eagle-Tribune 20 Mar 2026
NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ. NKTR) ... .
Edit

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

PR Newswire 20 Mar 2026
NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S ... Shareholders who purchased shares of NKTR during the class period ...
Edit

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: SueWallSt

PR Newswire 19 Mar 2026
Alert. Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment Compliance ... NKTR) securities of a pending securities class action. THE CASE ... YOUR OPTIONS. You may be entitled to compensation without payment of any out-of-pocket fees.
Edit

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR

PR Newswire 19 Mar 2026
NKTR) and certain officers ... 7980 ... The Company's lead product candidateis rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a novel, first-in-class regulatory T cell stimulator for the treatment of, inter alia, alopecia areata ... Attorney advertising ... 21%.
Edit

NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities ...

Nasdaq Globe Newswire 18 Mar 2026
Faruqi & Faruqi, LLP Securities Litigation PartnerJames (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options ... .
Edit

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to ...

Business Wire 18 Mar 2026
NKTR) securities of a pending securities class action. THE CASE ... YOUR OPTIONS ... Levi, Esq.
Edit

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky

PR Newswire 18 Mar 2026
Alert. Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment Compliance ... NKTR) securities of a pending securities class action. THE CASE ... YOUR OPTIONS. You may be entitled to compensation without payment of any out-of-pocket fees.
×